Unveiling the Polypharmacological Potency of FDA-Approved Rebamipide for Alzheimer’s Disease

Unveiling the Polypharmacological Potency of FDA-Approved Rebamipide for Alzheimer’s Disease

<b>Background:</b> Alzheimer’s disease (AD) is a multifactorial neurodegenerative disorder characterised by the accumulation of neurotoxic substances in the brain, ultimately leading to progressive cognitive decline. The complex aetiology and involvement of multiple molecular targets in...

Full description

Saved in:
Bibliographic Details
Main Authors: Israa J. Hakeem, Hadil Alahdal, Hanadi M. Baeissa, Tahani Bakhsh, Misbahuddin Rafeeq, Alaa Hamed Habib, Mohammed Matoog Karami, Maryam A. AL-Ghamdi, Ghadeer Abdullah, Abeer Al Tuwaijri
Format: Article
Language:English
Published: MDPI AG 2025-05-01
Series:Pharmaceuticals
Subjects:
Alzheimer’s disease
multitargeted docking
FDA
Rebamipide
MD simulations
Online Access:https://www.mdpi.com/1424-8247/18/6/772
Tags: Add Tag
No Tags, Be the first to tag this record!

Internet

https://www.mdpi.com/1424-8247/18/6/772

Similar Items